Healthcare Sector
Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
01/17/2025 | CALL | $12.50 | 7,663 | +99 | +1.31% |
07/18/2025 | CALL | $10.00 | 622 | +51 | +8.93% |
04/17/2025 | PUT | $10.00 | 392 | +30 | +8.29% |
01/15/2027 | CALL | $15.00 | 58 | +25 | +75.76% |
01/16/2026 | CALL | $7.50 | 643 | +20 | +3.21% |
04/17/2025 | CALL | $12.50 | 471 | +12 | +2.61% |
01/17/2025 | CALL | $10.00 | 2,587 | -2 | -0.08% |
01/16/2026 | CALL | $10.00 | 1,848 | -7 | -0.38% |
01/17/2025 | CALL | $15.00 | 12,161 | -10 | -0.08% |
01/17/2025 | PUT | $15.00 | 15 | -19 | -55.88% |
12/20/2024 | PUT | $12.50 | 0 | -27 | -100.00% |
01/17/2025 | CALL | $7.50 | 1,220 | -78 | -6.01% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
SPDR (R) Ser Tr-SPDR� Kensho New Economies Composite ETF | 2.76% | 1.79M | 13.78M |
Vanguard Total Stock Market Index Fund | 2.37% | 1.53M | 11.81M |
iShares Russell 2000 ETF | 1.63% | 1.06M | 8.14M |
Vanguard Extended Market Index Fund | 1.06% | 683.23k | 5.27M |
Fidelity Small Cap Index Fund | 0.61% | 393.73k | 3.04M |
Invesco ETF Tr II-Invesco DWA Small Cap Momentum ETF | 0.42% | 273.91k | 2.11M |
Fidelity Extended Market Index Fund | 0.39% | 253.96k | 1.96M |
iShares Russell 2000 Growth ETF | 0.35% | 227.62k | 1.75M |
Russell Inv Co- Tax-Managed U.S. Mid & Small Cap Fund | 0.28% | 178.93k | 1.38M |
iShares Russell 2000 Value ETF | 0.26% | 169.92k | 1.31M |
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
10/07 10:00 am
GlobeNewswire Inc.
Read moreLiquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
10/02 06:00 am
GlobeNewswire Inc.
Read moreU.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
08/19 06:00 am
GlobeNewswire Inc.
Read moreLiquidia corp chief medical officer sells $18.4k in stock - Investing.com
07/15 09:39 pm
Investing.com
Read moreLiquidia Corp executive sells over $14k in company stock - Investing.com
07/15 06:47 pm
Investing.com
Read moreForecasting The Future: 5 Analyst Projections For Liquidia
06/25 03:00 pm
Benzinga
Read moreLiquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
06/18 08:42 am
GlobeNewswire Inc.
Read more7 Analysts Have This To Say About Liquidia
06/03 08:00 am
Benzinga
Read moreLiquidia Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
05/15 08:01 am
Benzinga
Read moreDown -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)
05/14 09:35 am
Zacks Investment Research
Read moreLiquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
05/13 05:43 pm
GlobeNewswire Inc.
Read moreDeciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
05/10 08:50 am
Zacks Investment Research
Read moreLiquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
05/10 08:00 am
GlobeNewswire Inc.
Read moreArvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
05/07 08:15 am
Zacks Investment Research
Read moreWill Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
04/26 10:00 am
Zacks Investment Research
Read moreEarnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline
04/25 10:02 am
Zacks Investment Research
Read moreLiquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
04/02 09:00 am
GlobeNewswire Inc.
Read moreThe Analyst Landscape: 5 Takes On Liquidia
04/01 02:00 pm
Benzinga
Read moreUpdate on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
04/01 06:00 am
GlobeNewswire Inc.
Read moreUnveiling 6 Analyst Insights On Liquidia
03/13 05:00 pm
Benzinga
Read moreLiquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates
03/13 07:10 am
Zacks Investment Research
Read moreLiquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
03/13 06:00 am
GlobeNewswire Inc.
Read moreArcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
03/07 06:10 pm
Zacks Investment Research
Read moreEarnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
03/07 11:00 am
Zacks Investment Research
Read moreLiquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
03/06 07:30 am
GlobeNewswire Inc.
Read moreArbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
02/29 09:40 am
Zacks Investment Research
Read moreArvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
02/27 09:30 am
Zacks Investment Research
Read moreUnited Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
02/22 01:22 pm
Zacks Investment Research
Read moreStrength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
02/19 06:54 am
Zacks Investment Research
Read moreThis United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
02/12 12:00 pm
Benzinga
Read moreLiquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
01/30 07:30 am
GlobeNewswire Inc.
Read moreWall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet
01/29 10:55 am
Zacks Investment Research
Read moreLiquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
01/25 07:00 am
GlobeNewswire Inc.
Read moreLiquidia Corporation Announces Updates to Operations Leadership
01/19 07:30 am
GlobeNewswire Inc.
Read moreWall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to Trade
01/09 07:21 pm
Zacks Investment Research
Read moreWhat Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now?
01/09 05:56 pm
Zacks Investment Research
Read moreLiquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
01/08 09:22 am
GlobeNewswire Inc.
Read moreDecoding 5 Analyst Evaluations For Liquidia
01/05 09:00 am
Benzinga
Read moreLiquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
01/05 07:45 am
GlobeNewswire Inc.
Read moreLiquidia Corporation Announces $100 Million in New Financings
01/04 10:10 am
GlobeNewswire Inc.
Read moreLiquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
01/02 07:45 am
GlobeNewswire Inc.
Read moreB of A Securities Maintains Buy Rating for Liquidia: Here's What You Need To Know
12/21 01:00 pm
Benzinga
Read moreU.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
12/20 05:56 pm
GlobeNewswire Inc.
Read more